Claris Biotherapeutics has raised $118 million in a Series B financing to advance its experimental eye drop, CSB-001, into pivotal testing in 2027 for the blinding corneal disease limbal stem cell deficiency (LSCD).
The funds will support late-stage clinical development, including planned pivotal studies in the first half of 2027 involving about 400 LSCD patients, primary efficacy endpoints focused on visual acuity and anatomical measures.
Claris will also use the proceeds to advance ongoing proof-of-concept and non-interventional natural history studies in LSCD, as well as pre-commercialization activities, with proof-of-concept data expected in the second half of 2026.
Sources:
07-28-2026 Press Releases from Claris Bio
An eye drug biotech banks $118M and stocks its executive ...
Novo Holdings-backed Claris Bio emerges with $118M
Latest News and Press Releases
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Fierce Biotech Fundraising Tracker '26: Crystalys culls $130M; AdvanCell adds $315M